Shoulder regeneration Tempe means asking about care that may use parts of your blood

Daily wear and repeated reaching often cause gradual soreness

A shoulder can slowly become sore as the joint stiffens or nearby cords become irritated. These cords, called tendons, join muscle to bone and help move the arm. The ache may rise when you dress, lift a bag or sleep on that side. Arthritis can also make movement rough and limited.

A fall changes what you need to watch. Prompt care matters if the arm suddenly feels weak or the shoulder looks out of shape. Neck trouble may send numbness or soreness down the arm. An exam can tell whether the trouble starts in the shoulder or neck before you choose care.

Lighter work and gentle motion can calm the shoulder

Work in shorter stretches and rest before the ache becomes strong. Try sleeping on your back or the other side. A warm or cold pack may help, so use the one that feels better. Don't push a stretch through sharp soreness.

Book a visit if sleep, dressing or reaching stays difficult. Get prompt help for fever, redness, sudden weakness or a hot, swollen shoulder. Seek emergency help if shoulder discomfort comes with chest tightness, hard breathing, nausea or sweat. At QC Kinetix, a medical provider, meaning the person who checks your shoulder, may offer regenerative treatment using concentrated blood parts there.

Sources

1. In the MOON Shoulder prospective cohort of 452 patients with symptomatic, ATRAUMATIC full-thickness rotator cuff tears, physical therapy succeeded in more than 70% of patients at 10 years: only 115 (27.0%) had surgery at any point over the decade. Patient-reported outcomes improved with physical therapy and did NOT decline over 10 years in those who never had surgery. The strongest predictor of early surgery was low patient expectation of physical therapy, not tear anatomy.

   Kuhn JE, et al. — The Predictors of Surgery for Symptomatic, Atraumatic Full-Thickness Rotator Cuff Tears Change Over Time: Ten-Year Outcomes of the MOON Shoulder Prospective Cohort.. J Bone Joint Surg Am, 2024. DOI: 10.2106/JBJS.23.00978.

2. In a nationally representative Finnish population sample of 602 adults aged 41-76 who had bilateral 3-Tesla shoulder MRI regardless of symptoms, rotator cuff abnormalities were found in 98.7% of participants (25% tendinopathy, 62% partial-thickness tear, 11% full-thickness tear). Abnormalities were present in 96% of ASYMPTOMATIC shoulders. Only full-thickness tears were more common in symptomatic shoulders, and that difference all but disappeared after adjustment (absolute difference 0.8%, 95% CI -3.4% to 6.0%).

   Ibounig T, et al. — Incidental Rotator Cuff Abnormalities on Magnetic Resonance Imaging.. JAMA Intern Med, 2026. DOI: 10.1001/jamainternmed.2025.7903.

3. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.

4. Semi-structured interviews with 25 academic specialists - cardiology, ophthalmology, ORTHOPEDICS, pulmonology and neurology - on how they counsel patients asking about experimental stem cell and regenerative interventions. Orthopedists relied most heavily on informational approaches: explaining the science, sharing risks, providing principles. Reported challenges included wanting to support a patient's decision while worrying about harms, and addressing stem cell hype and unrealistic expectations.

   Smith C, et al. — Academic Physician Specialists' Approaches to Counseling Patients Interested in Unproven Stem Cell and Regenerative Therapies-A Qualitative Analysis.. Mayo Clinic proceedings, 2021. DOI: 10.1016/j.mayocp.2021.06.026.

5. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

6. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature medicine, 2023. DOI: 10.1038/s41591-023-02632-w.